Hot Features
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/... Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.08 | -3.6036036036 | 2.22 | 2.35 | 2.1 | 26618 | 2.11973834 | CS |
| 4 | -0.18 | -7.75862068966 | 2.32 | 2.4314 | 2.1 | 23038 | 2.20245221 | CS |
| 12 | 0 | 0 | 2.14 | 2.5 | 1.81 | 27837 | 2.12819161 | CS |
| 26 | -1.53 | -41.689373297 | 3.67 | 3.89 | 1.75 | 441584 | 3.10746143 | CS |
| 52 | -10.71 | -83.3463035019 | 12.85 | 12.87 | 1.75 | 354048 | 4.00154799 | CS |
| 156 | -10.71 | -83.3463035019 | 12.85 | 12.87 | 1.75 | 354048 | 4.00154799 | CS |
| 260 | -10.71 | -83.3463035019 | 12.85 | 12.87 | 1.75 | 354048 | 4.00154799 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.